Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis

NCT07201051 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07201051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07201051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Recruiting
Start date
October 30, 2025
Completion date
December 10, 2027
Enrollment
363 (estimated)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis